Form 4: Twist Bioscience CAO Plans Share Sale for Tax Withholding

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, reported a planned sale of 235 shares of common stock to cover tax withholding obligations.

Summary

• Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp, reported a planned sale of common stock.
• The transaction, scheduled for September 8, 2025, involves the disposition of 235 shares of TWST common stock.
• The shares are to be sold at a price of $25.76 per share.
• Following this planned transaction, Robert F. Werner will beneficially own 48,454 shares of common stock.
• The sale is not a discretionary trade but is mandated to cover tax withholding obligations related to the vesting of Restricted Stock Units under the company's equity incentive plans.
• The transaction is being made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale.

Sentiment

Score: 5

Explanation: A score of 5 indicates neutrality. The transaction is a non-discretionary 'sell to cover' for tax purposes, which is a routine event and does not reflect a positive or negative sentiment towards the company's prospects from the insider.

Management Comments

• The sale represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
• These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

This is a routine insider transaction for tax purposes, common across all industries when restricted stock units vest, and does not reflect specific industry trends for biotechnology or synthetic biology.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine, non-discretionary tax-related sale, not indicative of a change in insider sentiment or company fundamentals.

Key Dates

Recommendation

The reported transaction is a non-discretionary 'sell to cover' to satisfy tax obligations upon RSU vesting, a common and expected event for executive compensation. It does not reflect a change in the insider's view of the company's prospects or fundamental performance. Therefore, it provides no new information to warrant a change in investment recommendation, suggesting a 'hold' position based solely on this filing.

Keywords

Twist Bioscience, TWST, Insider Transaction, Form 4, Robert F. Werner, Chief Accounting Officer, Stock Sale, Tax Withholding, Restricted Stock Units, Equity Incentive Plan, 10b5-1 Plan